IPW

OCT 0 3 7005 8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APP/ICANT:

C. Frank Bennett, et al.

APPLICATION NO.:

10/633,843

FILING DATE:

August 4, 2003

TITLE:

Antisense Modulation Of Superoxide Dismutase 1, Soluble

Expression

EXAMINER:

Unknown

GROUP ART UNIT:

1645

ATTY. DKT. NO.:

23546-10350 (ISPH-0756)

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below:

Dated

9/29/05

By: A Horal

Susan T. Hubl, Reg. No.: 47,668

COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT Under 37 CFR §§ 1.56 and 1.97-98

SIR:

Pursuant to the provisions of 37 CFR §§ 1.56 and 1.97-98, enclosed herewith is modified form PTO/SB/08A listing references for consideration by the Examiner.

The filing of this Information Disclosure Statement shall not be construed as a representation regarding the completeness of the list of references, or that inclusion of a reference in this list is an admission that it is prior art or is pertinent to this application, or that a search has been made, or as an admission that the information listed is, or may be considered to be, material to patentability, or that no other material information exists, and shall not be construed as an admission against interest in any manner.

This Information Disclosure Statement is being filed:

- within three months of the filing date of the application, or date of entry into the national stage of an international application, or before the mailing date of a first office action on the merits, whichever event last occurred;
- Enclosed is a copy of each listed reference that may be material to the examination of this application, and for which there may be a duty to disclose.
- This application was filed after June 30, 2003. Therefore, pursuant to the waiver of the requirements under 37 CFR 1.98(a)(2)(i), copies of each U.S. Patent and each



U.S. Patent Application Publication are not required to be submitted. Copies of any foreign patent documents and non-patent literature cited herein are enclosed. Applicant submits that no fee is required for the consideration of this Information Disclosure Statement.

Consideration of the listed references and favorable action are solicited.

Respectfully submitted, C. FRANK BENNETT, *ET AL*.

Dated:	9/2	9/05	_ B

By: Mynn 7 Hml

Susan T. Hubl, Reg. No.: 47,668 Fenwick & West LLP

Silicon Valley Center 801 California Street

Mountain View, CA 94041

Tel.: (415) 875-2316 Fax.: (650) 938-5200

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			PTO	Complete if Known		
INFORMATION DISCLOSURE				Application No.	10/633,843	
STATEMENT BY APPLICANT				Filing Date	August 4, 2003	
			PLICANT	First Named Inventor	C. Frank Bennett, et al.	
				Art Unit	1645	
5 2nt 9/29/05				Examiner Name	Unknown	
Sheet	1	of	21	Attorney Docket Number	23546-10350 (ISPH-0756)	

U.S. PATENT DOCUMENTS				
		Document No.		
Examiner Initials*	Cite No.1	Number – Kind Code ² (if known)	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	A1	US-5,849,290	12/1998	Brown, et al.
	A2	US-5,994,076	11/1999	Chenchik et al.
<u></u>	А3	US-6,077,833	06/2000	Bennett et al.
	A4	US-5,801,154	09/1998	Baracchini et al.
-1-	A5	US-5,998,148	12/1999	Bennett et al.

		OTHER REFERENCES - NON-PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
	B1	Misra et al. Drug delivery to the central nervous system: a review. J. Phar Pharmaceut Sci, 2003 Vol. 6(2) pages 252-273 Elsevier	
	B2	Grzanna et al. Intrastriatal and intraventricular injections of oligodeoxynucleotides in the rat brain: tissue penetration, intracellular distribution and c-fos antisense effects. Molecular Brain Research, 1998 Vol. 63, pages 35-52. Elsevier	٠
	В3	Green et al. Antisense Oligonucleotides: An Evolving Technology for the Modulation Of Gene Expression in Human Disease. Antisense Therapy in Human Disease (2000) Vol. 191: pages 93-105. Elsevier Science Inc	
	B4	Jen et al. Suppression of Gene Expression by Targeted Disruption Of Messenger RNA: Available Options and Current Strategies. Stem Cells (2000) Vol. 18; pages 307-319. AlphaMed Press.	
	B5	Branch et al. A Good Antisense Molecule is Hard to Find. TIBS (1998) Vol. 23, pages 45-50. Elsevier Science LTD.	
	B6	Crooke, ST, Basic Principles Of Antisense Therapeutics. Antisense Research An Application (1998), Chapter 1 Springer-Verlag, New York.	

	 	· · · · · · · · · · · · · · · · · · ·
Examiner	Date	
Signature	Considered	
•		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.